WEATHER ALERT: January 25, 2026 (5:15 PM): We are actively monitoring the weather in our area to ensure patient and staff safety. Our offices will be CLOSED on Monday (January 26) with an ON-TIME OPENING on Tuesday (January 27). Patients in active cancer treatment will continue to be prioritized to ensure continuity of care. If you are undergoing active cancer treatment, a team member will reach out to advise of any changes to your appointment. Please continue to check our website for the latest weather updates. Thank you for your patience and understanding.
A cancer vaccine comprised of multiple synthetic breast cancer peptides and the adjuvant tetanus toxoid helper peptide emulsified in the adjuvant Montanide ISA-51 with immunopotentiation activity. Vaccination with this cancer vaccine may elicit a specific cytotoxic T-lymphocyte response against breast cancer cells. Synthetic breast cancer peptides may stimulate the immune response against cells that produce breast cancer markers such as erbB2 (HER2/neu) while tetanus toxoid helper peptide binds to class II MHC molecules as a nonspecific vaccine helper epitope, resulting in a long-term immunopotentiation by increasing the helper T-cell response. Montanide ISA-51, also known as incomplete Freund’s adjuvant or IFA, is a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant that non-specifically stimulates cell-mediated immune responses to antigens. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
